In bladder cancer, HMGN5 silencing could block the PI3K/Akt signaling pathway, therefore improving the chemical sensitivity of human bladder cancer cells to cisplatin, whereby the viability and invasion of these cells could be inhibited in vitro and in vivo [7]. Here, AKT1 is linked to urinary bladder cancer.